08 Nov GLP-1 Medications for Weight Loss: What the Trials Show and What Patients Should Ask Firs
Prescription Medication Notice: Semaglutide and tirzepatide are prescription medications and should only be prescribed and monitored by your healthcare provider. Do not use them if you or a family member has had medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, or if you are pregnant or planning pregnancy. Tell your provider about all medications you take, especially insulin or a sulfonylurea. Seek prompt medical care for severe or persistent abdominal pain, which can be a sign of pancreatitis, for pain in the upper right abdomen or yellowing of the skin, or for severe vomiting or diarrhea that leaves you unable to keep fluids down. Compounded versions are not FDA-approved.
Editorial Notice: This article is general information and is not specific medical advice. Programs and providers named or linked in this article are not warranted or endorsed by MedicalResearch.com or Eminent Domains Inc.
GLP-1 medications have changed how doctors treat obesity in only a few years. Semaglutide and tirzepatide now produce weight loss in clinical trials that approaches what was once seen mainly with surgery, and demand has grown well beyond what most primary care offices can handle.
Wherever a patient starts, it helps to understand what the research supports, where the limits are, and which questions to raise before the first dose.